Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vistagen Therapeutics (VTGN) Interest Expenses (2017 - 2019)

Historic Interest Expenses for Vistagen Therapeutics (VTGN) over the last 6 years, with Q4 2019 value amounting to -$1500.0.

  • Vistagen Therapeutics' Interest Expenses fell 18333.33% to -$1500.0 in Q4 2019 from the same period last year, while for Sep 2020 it was -$1500.0, marking a year-over-year decrease of 13125.0%. This contributed to the annual value of $8000.0 for FY2019, which is 1011.24% down from last year.
  • According to the latest figures from Q4 2019, Vistagen Therapeutics' Interest Expenses is -$1500.0, which was down 18333.33% from $1800.0 recorded in Q4 2018.
  • In the past 5 years, Vistagen Therapeutics' Interest Expenses ranged from a high of $3000.0 in Q2 2017 and a low of -$1500.0 during Q4 2019
  • In the last 3 years, Vistagen Therapeutics' Interest Expenses had a median value of $2000.0 in 2017 and averaged $1787.5.
  • As far as peak fluctuations go, Vistagen Therapeutics' Interest Expenses changed by 0.0% in 2018, and later tumbled by 18333.33% in 2019.
  • Vistagen Therapeutics' Interest Expenses (Quarter) stood at $2000.0 in 2017, then dropped by 10.0% to $1800.0 in 2018, then tumbled by 183.33% to -$1500.0 in 2019.
  • Its Interest Expenses stands at -$1500.0 for Q4 2019, versus $1800.0 for Q4 2018 and $3000.0 for Q3 2018.